Share

Research Interrupted: Scientists Are Heeding the Call to Treat COVID-19 Patients

EN0620_cover Endocrine News spoke to two early-career researchers who were called into action to treat COVID-19 patients full time. They share their inspiring stories of how they are coping with their new duties, how their research informed their patients’ care, and what they think the future of healthcare will look like post-pandemic. Endocrine scientists routinely spend...
Share

Virtual Endocrinology: The Rise of Telemedicine During COVID-19

july cover How clinicians treat patients has been drastically reimagined during the COVID-19 pandemic due to social distancing requirements. Since patients still need to see their doctors one way or another, telemedicine has filled the gap and has been embraced by both the healthcare community and patients alike. Chirag R. Kapadia, MD, is an endocrinologist at Phoenix...
Share

Best Laid Plans: Managing COVID-19 in Hospital Settings

A series of papers to be published across a variety of journals provides a potential roadmap for treating COVID-19 patients within a hospital setting. It tells practitioners in these healthcare environments how to prepare for the unexpected. On April 30, an article appeared in the New England Journal of Medicine titled “Best Practices for a...
Share

COVID-19 Damages the Endocrine System

People with endocrine disorders may see their condition worsen as a result of COVID-19, according to a new review published in the Journal of the Endocrine Society. “We explored the previous SARS outbreak caused by the very similar virus SARS-CoV-1 to advise endocrinologists involved in the care of patients with COVID-19,” says Noel Pratheepan Somasundaram...
Share

Expert Opinion: COVID-19 & RAS Blockers

The theoretical threat from blood pressure medicine’s effects on COVID-19 caused many patients on these medications to make panicked calls to their healthcare providers. However, a group of professional associations and researchers moved quickly to counter this fear — and to recommend that patients infected with COVID-19 should continue taking renin-angiotensin system (RAS) blockers in...
Share

Diabetic Ketoacidosis Threatens Hospitalized COVID-19 Patients

Diabetic ketoacidosis is a common and potentially fatal complication in hospitalized patients with COVID-19, according to a new clinical perspective published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Diabetic ketoacidosis almost always requires special care in the hospital which usually takes place in the intensive care unit (ICU). It is caused by insufficient insulin circulating in the bloodstream, which is more likely to occur during a serious infection like COVID-19. Diabetic...
Share

Endocrine Society Issues Statement on Dexamethasone & COVID-19

On June 17, the Endocrine Society issued a statement on the efficacy of using dexamethasone in COVID-19 patients. Here is the statement in full: A new clinical trial out of the University of Oxford, United Kingdom, reports that dexamethasone reduced deaths in patients with severe COVID-19. It is imperative that our patients and the public...